Want to see AU:BP8 full AI Analyst Report?
Top Page
Stemcell United Ltd.
(Sydney:BP8)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.06
▲(384.62% Upside)
Action:Reiterated
Date:09/06/26
The score is primarily held down by weak financial performance—negative gross profit, persistent losses, negative equity, and ongoing cash burn—despite a strong FY2026 revenue rebound. Valuation is also pressured by a negative P/E (loss-making) and no provided dividend yield, while technicals are neutral due to missing indicator data.
Positive Factors
Sharp Revenue Rebound
The substantial FY2026 revenue rebound indicates improved commercial traction and stronger customer demand compared with the prior year. If the higher sales level persists, it could provide a broader base for operating leverage, reinvestment, and eventual margin improvement.
Negative Factors
Persistent Unprofitability
Negative gross profit and a deeply negative net margin indicate that current sales are not yet producing an economically sustainable business model. Without meaningful improvement in unit economics and operating efficiency, revenue growth may continue to require funding rather than translate into durable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Sharp Revenue Rebound
The substantial FY2026 revenue rebound indicates improved commercial traction and stronger customer demand compared with the prior year. If the higher sales level persists, it could provide a broader base for operating leverage, reinvestment, and eventual margin improvement.
Read all positive factors
Stemcell United Ltd. (BP8) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$2.35M
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)-0.35
Revenue Growth877.51%
EPS Growth61.54%
CountryAU
Employees31
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,353,484,600
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-2.06
Price to Sales (P/S)0.52
P/FCF Ratio-0.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Stemcell United Ltd. Business Overview & Revenue Model
Company Description
BPH Global Ltd, along with its associated entities, specializes in the procurement, production, promotion, and sale of traditional medicinal items. Its operational reach spans Australia, Singapore, China, and the broader Southeast Asian market. Th...
How the Company Makes Money
null...
Stemcell United Ltd. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
15
Very Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.44M | 352.38K | 109.97K | 339.00 | 14.35M |
| Gross Profit | -890.49K | -678.01K | 18.27K | 339.00 | 2.29M |
| EBITDA | -1.76M | -1.45M | -1.76M | -3.52M | -2.49M |
| Net Income | -1.79M | -1.49M | -2.27M | -4.32M | -3.54M |
Balance Sheet | |||||
| Total Assets | 1.38M | 541.00K | 691.84K | 2.10M | 7.16M |
| Cash, Cash Equivalents and Short-Term Investments | 259.88K | 152.74K | 134.82K | 1.14M | 685.56K |
| Total Debt | 555.74K | 0.00 | 508.64K | 0.00 | 1.30M |
| Total Liabilities | 2.26M | 2.01M | 1.97M | 1.19M | 2.44M |
| Stockholders Equity | -868.82K | -1.45M | -966.82K | 530.13K | 3.20M |
Cash Flow | |||||
| Free Cash Flow | -2.14M | -932.18K | -1.26M | -1.49M | -4.93M |
| Operating Cash Flow | -2.14M | -929.81K | 0.00 | 0.00 | 0.00 |
| Investing Cash Flow | -8.38K | -2.37K | 185.33K | 6.29K | -914.21K |
| Financing Cash Flow | 2.44M | 962.99K | 697.04K | 1.38M | 281.27K |
Stemcell United Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$2.88B | -34.91 | -10.06% | ― | 555.67% | 49.08% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$13.54M | -2.74 | -164.96% | ― | -4.24% | 33.39% | |
49 Neutral | AU$197.44M | -13.68 | -36.83% | ― | 51.07% | -47.63% | |
44 Neutral | AU$2.35M | -1.04 | 216.63% | ― | 877.51% | 61.54% | |
41 Neutral | AU$2.68M | -0.29 | -607.23% | ― | ― | 15.04% | |
40 Underperform | AU$20.28M | -9.00 | -88.14% | ― | ― | -200.00% |
* Healthcare Sector Average
AU:BP8
Stemcell United Ltd.
―
―
―
AU:CYP
Cynata Therapeutics Limited
0.01
-0.18
-94.21%
AU:1AI
Living Cell Technologies
0.01
0.00
0.00%
AU:MSB
Mesoblast Limited
2.17
-0.04
-1.81%
AU:OCC
Orthocell Ltd
0.73
-0.40
-35.27%
AU:CMB
Regeneus Ltd.
0.46
-0.05
-9.80%
Stemcell United Ltd. Corporate Events
BPH Global Announces Board Resignation, Retains Advisory Role
Sep 4, 2026
BPH Global Ltd has announced the resignation of Non-Executive Director Yanhua Huang from its board, marking a change in the company’s governance composition. The board publicly acknowledged Huang’s contributions and extended best wishe...
BPH Global Revenue Surges but Losses Deepen Amid China Exit and Going-Concern Warning
Aug 31, 2026
BPH Global Limited reported a sharp 1,359.6% increase in revenue to $3.44 million for the year ended 30 June 2026, driven by its ongoing seaweed sales operations in Indonesia. Despite the revenue surge, the company’s net loss attributable to...
BPH Global Announces Consolidation of Shares, Options and Rights
Aug 11, 2026
BPH Global Ltd has announced a consolidation of its securities, affecting its ordinary fully paid shares, multiple series of listed options, and performance rights. The consolidation is scheduled with trading in post-consolidation securities to be...
BPH Global Calls September Extraordinary Meeting, Details Voting Process
Aug 11, 2026
BPH Global Limited has called an Extraordinary General Meeting for 11 September 2026 in Melbourne, providing shareholders with a detailed notice, agenda, and explanatory material. The company is directing investors to monitor its ASX announcements...
BPH Global Scales Indonesian Seaweed Platform and Refocuses on High-Value Products
Jul 31, 2026
BPH Global reported that its Indonesian seaweed trading operations have generated approximately A$3.33 million in aggregate gross sales over their first 12 months, with quarterly results improving as Makassar moved from the wet to the dry season, ...
BPH Global completes first direct seaweed export shipment to China
Jul 22, 2026
BPH Global Ltd has completed its first direct commercial shipment of raw seaweed from Indonesia to a customer in China, following regulatory approval under the Indonesia–China Mutual Recognition Arrangement. The cargo passed quality inspecti...
BPH Global boosts seaweed margins as direct China exports begin
Jul 13, 2026
BPH Global reported gross sales of IDR 5.33 billion (about AUD 535,895) from 15 May to 30 June 2026, taking aggregate sales since launching its Indonesian seaweed trading operations in May 2025 to IDR 45.49 billion (AUD 3.87 million). The results ...
BPH Global Opens Direct Seaweed Export Channel to China
Jul 8, 2026
BPH Global Ltd has begun direct exports of raw seaweed from its Makassar, Indonesia hub to China, following export approval from China’s customs authority under the Indonesia–China Mutual Recognition Arrangement. The first commercial s...
BPH Global Discloses Departure of Director Paul Stephenson and His Indirect Holdings
Jun 22, 2026
BPH Global Ltd has announced that director Paul Stephenson has ceased to be a director of the company as of 21 June 2026, with a formal notice provided to the ASX in line with listing rule requirements. The filing notes that Stephenson held no sec...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.